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Abstract In order to determine whether combination an-
tibiotic therapy decreases mortality after severe pneumo-
coccal infection, a retrospective study of a cohort of 1,840
adult patients with severe sepsis or septic shock enrolled in
two multicenter clinical trials between 1994 and 1999 was
conducted. Among 107 patients with monobacterial pneu-
mococcal sepsis, the case-fatality rate was 20% (five of 25)
for patients who received antibiotic monotherapy com-
pared with 19.5% (16 of 82) for patients who received
combination therapy (adjusted hazard ratio, 1.1; 95% CI,
0.4–3.1). Similarly, monotherapy did not increase the risk
of death (adjusted hazard ratio, 1.0; 95% CI, 0.2–4.8)
among bacteremic patients (n=75). However, the latter
analysis may have been underpowered (power, 58%) to
detect a difference in mortality. Overall, in contrast to re-
cently published reports, these results suggest that com-
bination antibiotic therapy does not decrease mortality after
severe pneumococcal sepsis.
Introduction
Severe pneumococcal sepsis remains a therapeutic chal-
lenge despite advances in supportive treatment. Several
recently published studies have suggested that combination
antibiotic therapy may improve survival among critically
ill patients with pneumococcal bacteremia [1–3]. Among
these, one international study including 844 patients from
ten countries observed that among 94 critically ill patients,
the 14-day mortality was 55% for patients receiving mono-
therapy compared with 23% for those receiving different
regimens of combination therapy (adjusted odds ratio, 2.9;
95% confidence interval [CI] 1.1–7.7) [3]. Based on these
findings, several experts have recommended that clinicians
should consider combination antibiotic therapy for sus-
pected or confirmed pneumococcal sepsis [3, 4].
To test this hypothesis and to assess the impact of
antibiotic monotherapy on survival after life-threatening
pneumococcal sepsis, we conducted a retrospective study
of a cohort of critically ill patients with severe sepsis or
septic shock caused by Streptococcus pneumoniae, who
were enrolled in two large clinical trials between 1994 and
1999 [5, 6].
Patients and methods
We reviewed a database containing data collected pro-
spectively from 1,840 adult patients with severe sepsis or
septic shock, who were enrolled in two placebo-controlled
multicenter trials to determine the safety and efficacy of
p55 IgG tumor necrosis factor receptor fusion protein
(lenercept) [5, 6]. In the final analysis, there was no
significant difference in 28-day mortality between patients
treated with placebo or lenercept [6]. Inclusion criteria,
details of the study design, and results of the trials have
been published elsewhere [5–7].
For the current retrospective analysis, we included all
patients >18 years of age who had severe sepsis or septic
shock caused by monobacterial, pneumococcal illness
(with or without positive blood cultures). The infection was
considered to be caused by S. pneumoniae when this or-
ganism was isolated from pure culture of a clinically
relevant sample [8]. Patients with neutropenia secondary to
chemotherapy, HIV infection and corticosteroid use
(>1 mg/kg/day) were excluded. Severity of illness at
baseline was calculated using a mortality risk prediction
model based on the Simplified Acute Physiology Score II
[6].
We defined monotherapy as receipt of a single antimi-
crobial agent within the first 48 h of treatment after study
inclusion, whereas combination therapy was defined as
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receipt of the same two agents during the first 48 h of
treatment [3]. As suggested by Baddour et al. [3], patients
who had inconsistent treatment regimens and changes in
antimicrobial treatment after 24 h of therapy were
excluded.
All patients received full standard supportive care and
antibiotic therapy. Antibiotic susceptibility testing was
performed at each participating institution. Organisms re-
ported as intermediately susceptible to a particular antibi-
otic were classified as sensitive for this report. The primary
study endpoint was the 28-day all-cause mortality.
We used the Student t test to compare continuous
variables and the chi-square test to compare proportions.
Mortality was explored graphically by plotting Kaplan-
Meier survival curves and was analyzed using Cox pro-
portional hazards regression. Results of standard tests
showed no disagreement with the proportional-hazards
assumption. The actual sample size of 107 patients gave the
study a power of 79% to detect a substantial increase in
mortality (from 23 to 55%, as observed in the study by
Baddour et al. [3]) after pneumococcal sepsis treated by
antibiotic monotherapy. Considering only bacteremic pa-
tients (n=75), our study had a power of 58% to detect a
similar increase in mortality during the course of severe
pneumococcal bacteremia. Assumptions included the use
of a two-tailed test and a 5% level of statistical significance.
Results and discussion
Among 167 patients with at least one specimen yielding S.
pneumoniae, 30 were excluded because of polymicrobial
infection or simple colonization (e.g., tracheobronchitis)
that was not considered causative of sepsis, and 30 others
could not be evaluated because of inconsistent treatment
regimens. Among the 107 remaining patients with mono-
bacterial pneumococcal illness causing severe sepsis or
septic shock, 25 (23%) received antibiotic monotherapy,
either with a penicillin agent (n=13), a third-generation
cephalosporin (n=10) or another agent (n=2). Combination
therapies prescribed were β-lactam agents/macrolides
(n=34), β-lactam/clindamycin (n=11), β-lactam/vancomy-
cin (n=10), aminoglycoside-containing regimens (n=9),
double β-lactam therapy (n=9), fluoroquinolone-contain-
ing regimens (n=6) or combination regimens including
other antibiotic classes (n=3). Two isolates expressed
resistance to penicillin and three isolates were resistant to
macrolides; none of these patients received antibiotic
monotherapy. Characteristics of the two patient groups are
presented in Table 1. Patients receiving antibiotic mono-
therapy were more likely to be enrolled in Europe, but the
two groups were well balanced for other baseline
characteristics.
Death occurred in 21 (19.6%) cases. The case-fatality
rate was 20% (5 of 25) among patients with antibiotic
monotherapy compared with 19.5% (16 of 82) among
patients receiving combination therapy. One of five (20%)
deaths in the monotherapy group occurred within 4 days
after hospital admission compared with 7 of 16 (44%)
deaths in the combination therapy group (p=0.61). None of
these prematurely deceased patients received inappropriate
initial antibiotic therapy.
Figure 1 illustrates survival curves for both cohorts. The
unadjusted hazard ratio (HR) for death following mono-
therapy was 1.0 (95% CI, 0.4–2.7; p=1.0). The risk of death
remained almost unchanged after adjusting for the number
of organ dysfunctions and the severity of illness at baseline
(adjusted HR, 1.1; 95% CI, 0.4–3.1; p=0.88). A separate
regression analysis, which stratified patients according to
their study drug allocation (lenercept vs. placebo) or
Table 1 Baseline characteristics of 107 patients with severe
pneumococcal sepsis, according to receipt of antibiotic monotherapy
or combination therapy
Characteristic Monotherapy Combination
therapy
p
value
(n=25) (n=82)
Age in years (mean±SD) 56±18 54±15 0.70
Male gender (%) 14 (56) 47 (57) 0.91
Study region, Europe (%) 15 (60) 31 (38) 0.05
Lenercept treatment (%) 12 (48) 43 (52) 0.70
Septic shock (%) 19 (76) 62 (76) 0.97
SAPS II risk quartiles (%) 0.44
1st (predicted mortality,
0–18%)
3 (12) 21 (26)
2nd (predicted mortality,
19–31%)
5 (20) 16 (20)
3rd (predicted mortality,
32–45%)
10 (40) 22 (27)
4th (predicted mortality,
>45%)
7 (28) 23 (28)
Organ dysfunctions (mean±SD) 1.2±1.0 1.5±1.1 0.46
Positive blood cultures (%) 16 (64) 59 (72) 0.45
SAPS Simplified Acute Physiology Scoring System
Fig. 1 Kaplan-Meier probability estimates of survival for patients
suffering from severe pneumococcal sepsis, stratified by receipt of
antibiotic monotherapy (n=25) vs. combination therapy (n=82). The
median interval to death was 20 days (interquartile range, 6–21
days) for the monotherapy group and 7 days (interquartile range, 2–
11 days) for the combination therapy group. The log-rank test was
not significant (p=0.99), thus demonstrating equality of the survivor
functions
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country (to avoid confounding by possible cluster effects),
confirmed this lack of association.
We observed 75 cases of pneumococcal bacteremia.
After stratifying for receipt of antibiotic monotherapy
(n=16; mortality, 12.5%) or combination therapy (n=59;
mortality, 20.3%), exposure to monotherapy was not
associated with a significantly increased risk of death
(adjusted HR, 1.0; 95% CI, 0.2–4.8). Among bacteremic
patients, the mortality rate was 15.9% (7 of 44) for those
who received a cephalosporin-containing combination reg-
imen as compared with 16.7% (1 of 6) for those who
received a third-generation cephalosporin as monotherapy
(HR, 1.1; 95% CI, 0.1–9.3).
These results do not confirm the recently reported
association between combination antibiotic therapy and
decreased risk of death after severe pneumococcal sepsis.
Several reasons may explain the discrepancy between our
findings and the results reported in the literature by others.
(i) Previous studies included mainly cases with bacteremic
pneumococcal pneumonia [1–3]. We included not only
patients with bacteremia, but also those with severe, blood
culture-negative pneumococcal sepsis. However, in our
subgroup analysis of 75 patients with positive blood
cultures, no different effect was observed. (ii) The sample
size of our study may have been too small to show a
deleterious effect of monotherapy in bacteremic patients.
For instance, once-daily dosing of ceftriaxone in critically
ill patients with hypoalbuminemia may shorten the half-life
of this agent and may cause inadequate bacterial killing
curves and adverse outcomes [9]. Considering the 95%
confidence interval of our estimates and the sample-size
calculations showing a power of 58%, we cannot exclude
the possibility that the analysis of patients with pneumo-
coccal bacteremia may have been underpowered. (iii) Our
analysis was based on two clinical trials conducted in the
1990s, when high-level resistance to penicillin was rare in
the participating centers. However, Baddour et al. [3]
reported that outcome in critically ill patients was not
influenced by whether or not patients received inappropri-
ate antibiotic therapy based on pneumococcal susceptibil-
ity results. (iv) Confounding by indication may bias the
findings of non-randomized studies [4]. This systematic
bias occurs when correct adjustments are not made for
imbalances in treatment assignment. To further control for
differences between patient groups, future studies should
use propensity scores [7]. (v) Only 41% (34/82) of patients
in the combination treatment group received a β-lactam/
macrolide combination, which has been suggested to be the
most beneficial for survival. However, in the study by
Baddour et al. [3], only 30% (14/47) of patients received a
macrolide-containing combination regimen and non-mac-
rolide combination regimens were also successful in
reducing mortality among critically ill patients. (vi) Since
HIV-positive and neutropenic patients were excluded, we
were not able to evaluate any harmful effect of mono-
therapy in these patient groups.
Important strengths of this analysis include the large size
and multinational nature of the cohort, the heterogeneity of
the patient population, and the detailed data on illness
severity, evolving organ dysfunctions and antibiotic treat-
ment. All variables were collected prospectively, validated
rigorously due to the requirements of the original trial
protocol, and analyzed using survival regression methods,
which adjust for the time interval between onset of
pneumococcal sepsis and discharge or death.
Overall, our results suggest that although antibiotic
monotherapy is not frequently used as empiric treatment
for severe pneumococcal sepsis, it may not be independ-
ently associated with 28-day mortality. Therefore, we
believe that caution should be applied when generalizing
previously reported findings to other settings and patient
populations.
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